AIHTA - Publications - Search - Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)

Grössmann, N. (2020): Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Oncology Fact Sheet Nr. 19.

[thumbnail of Oncology Fact Sheet Nr.19.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
81kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WH Hemic and lymphatic systems
Language:English
Series Name:Oncology Fact Sheet Nr. 19
Deposited on:20 Aug 2020 13:11
Last Modified:20 Aug 2020 13:15

Repository Staff Only: item control page